128 related articles for article (PubMed ID: 31201406)
1. Serum biomarkers for glioblastoma multiforme.
Quddusi A; Shamim MS
J Pak Med Assoc; 2019 Jun; 69(6):913-914. PubMed ID: 31201406
[TBL] [Abstract][Full Text] [Related]
2. Serum concentrations of glial fibrillary acidic protein (GFAP) do not indicate tumor recurrence in patients with glioblastoma.
Vietheer JM; Rieger J; Wagner M; Senft C; Tichy J; Foerch C
J Neurooncol; 2017 Oct; 135(1):193-199. PubMed ID: 28717884
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma.
Gállego Pérez-Larraya J; Paris S; Idbaih A; Dehais C; Laigle-Donadey F; Navarro S; Capelle L; Mokhtari K; Marie Y; Sanson M; Hoang-Xuan K; Delattre JY; Mallet A
Cancer; 2014 Dec; 120(24):3972-80. PubMed ID: 25139333
[TBL] [Abstract][Full Text] [Related]
4. Neuro-oncology: a step towards clinical blood biomarkers of glioblastoma.
Preusser M
Nat Rev Neurol; 2014 Dec; 10(12):681-2. PubMed ID: 25366110
[TBL] [Abstract][Full Text] [Related]
5. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
[TBL] [Abstract][Full Text] [Related]
6. Glial Fibrillary Acidic Protein in the Diagnosis and Prognosis of Malignant Glial Tumors.
Lyubimova NV; Timofeev YS; Mitrofanov AA; Bekyashev AK; Goncharova ZA; Kushlinskii NE
Bull Exp Biol Med; 2020 Feb; 168(4):503-506. PubMed ID: 32147765
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma.
Tichy J; Spechtmeyer S; Mittelbronn M; Hattingen E; Rieger J; Senft C; Foerch C
J Neurooncol; 2016 Jan; 126(2):361-9. PubMed ID: 26518540
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.
Yue X; Lan F; Hu M; Pan Q; Wang Q; Wang J
J Neurosurg; 2016 Jan; 124(1):122-8. PubMed ID: 26230475
[TBL] [Abstract][Full Text] [Related]
9. Serum expression level of miR-504 can differentiate between glioblastoma multiforme and solitary brain metastasis of non-small cell lung carcinoma.
Jin Z; Jin RH; Ma C; Li HS; Xu HY
J BUON; 2017; 22(2):474-480. PubMed ID: 28534372
[TBL] [Abstract][Full Text] [Related]
10. Integrated Cox's model for predicting survival time of glioblastoma multiforme.
Ai Z; Li L; Fu R; Lu JM; He JD; Li S
Tumour Biol; 2017 Apr; 39(4):1010428317694574. PubMed ID: 28381184
[TBL] [Abstract][Full Text] [Related]
11. Preoperative biomarkers of tumour vascularity are elevated in patients with glioblastoma multiforme.
Bennett IE; Guo H; Kountouri N; D'abaco GM; Hovens CM; Moffat BA; Desmond P; Drummond K; Kaye AH; Morokoff AP
J Clin Neurosci; 2015 Nov; 22(11):1802-8. PubMed ID: 26308396
[TBL] [Abstract][Full Text] [Related]
12. Circulating miR-26a and miR-21 as biomarkers for glioblastoma multiform.
ParvizHamidi M; Haddad G; Ostadrahimi S; Ostadrahimi N; Sadeghi S; Fayaz S; Fard-Esfahani P
Biotechnol Appl Biochem; 2019 Mar; 66(2):261-265. PubMed ID: 30408234
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the Effects of MicroRNA-221 Expression Levels in Glioblastoma Multiforme Tumors.
Ozdogan S; Yaltirik CK; Yilmaz SG; Akdeniz FT; Sumerkent K; Duzkalir AH; Ture U; Isbir T
Anticancer Res; 2020 Jun; 40(6):3265-3270. PubMed ID: 32487621
[TBL] [Abstract][Full Text] [Related]
14. Serum miR-100 is a potential biomarker for detection and outcome prediction of glioblastoma patients.
Zhang H; Wang J; Wang Z; Ruan C; Wang L; Guo H
Cancer Biomark; 2019; 24(1):43-49. PubMed ID: 30530966
[TBL] [Abstract][Full Text] [Related]
15. Emerging circulating biomarkers in glioblastoma: promises and challenges.
Touat M; Duran-Peña A; Alentorn A; Lacroix L; Massard C; Idbaih A
Expert Rev Mol Diagn; 2015; 15(10):1311-23. PubMed ID: 26394701
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of plasma d-dimer levels in patients with glioblastoma multiforme - Results from a pilot study.
Hoke M; Dieckmann K; Koppensteiner R; Schillinger M; Marosi C; Mlekusch W
Wien Klin Wochenschr; 2011 Apr; 123(7-8):199-203. PubMed ID: 21442202
[TBL] [Abstract][Full Text] [Related]
17. [The glio-fibrillar acid protein in blood serum of patients with brain tumors and neurological diseases of non-tumorous etiology].
Lyubimova NV; Timofeiev YS; Sushlinskii NE
Klin Lab Diagn; 2016 Aug; 61(8):466-9. PubMed ID: 30601636
[TBL] [Abstract][Full Text] [Related]
18. Reduced circulating microRNA-203 predicts poor prognosis for glioblastoma.
Chen J; Yang L; Wang X
Cancer Biomark; 2017 Dec; 20(4):521-526. PubMed ID: 28946553
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival.
Kiviniemi A; Gardberg M; Frantzén J; Parkkola R; Vuorinen V; Pesola M; Minn H
J Neurooncol; 2015 Sep; 124(2):237-45. PubMed ID: 26033547
[TBL] [Abstract][Full Text] [Related]
20. Routine Blood Tests Do Not Predict Survival in Patients with Glioblastoma-Multivariable Analysis of 497 Patients.
Maas SLN; Draaisma K; Snijders TJ; Senders JT; Berendsen S; Seute T; Schiffelers RM; van Solinge WW; Ten Berg MJ; Robe PA; Broekman MLD
World Neurosurg; 2019 Jun; 126():e1081-e1091. PubMed ID: 30880204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
